STOCK TITAN
  1. Home
  2. Sec-filings
  3. RLMD
  4. [Form 4] RELMADA THERAPEUTICS, INC. Insider Trading Activity

Relmada Therapeutics (RLMD) CEO reports share buys and stock rights

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Relmada Therapeutics CEO and director Sergio Traversa reported buying 27,500 shares of the company’s common stock in multiple open market transactions at a weighted average price of $4.12 per share, with individual purchase prices ranging from $4.10 to $4.12.

Following these purchases, he beneficially owns 1,300,000 common shares directly. Traversa was also granted 1,198,000 stock appreciation rights with a conversion price of $4.06, each linked to one share of common stock. These rights vest in 16 equal quarterly installments beginning on March 12, 2026 and expire on December 12, 2035, with 1,198,000 derivative securities shown as beneficially owned after the transaction.

Positive

  • None.

Negative

  • None.
Insider TRAVERSA SERGIO
Role Chief Executive Officer
Bought 27,500 shs ($113K)
Type Security Shares Price Value
Purchase Common Stock 27,500 $4.12 $113K
Grant/Award Stock Appreciation Rights 1,198,000 $0.00 --
Holdings After Transaction: Common Stock — 1,300,000 shares (Direct); Stock Appreciation Rights — 1,198,000 shares (Direct)
Footnotes (1)
  1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Purchase prices range from $4.10 to $4.12 per share, inclusive. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
TRAVERSA SERGIO
(Last) (First) (Middle)
C/O RELMADA THERAPEUTICS, INC.
2222 PONCE DE LEON BLVD, 3RD FLOOR
(Street)
CORAL GABLES FL 33134
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/15/2025 P 27,500(1) A $4.12(2) 1,300,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Rights $4.06 12/12/2025 A 1,198,000 03/12/2026(3) 12/12/2035 Common Stock 1,198,000 $0 1,198,000 D
Explanation of Responses:
1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
2. Purchase prices range from $4.10 to $4.12 per share, inclusive.
3. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
/s/ Sergio Traversa 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Relmada Therapeutics (RLMD) report in this filing?

The filing shows that CEO and director Sergio Traversa purchased 27,500 shares of Relmada Therapeutics common stock in open market transactions.

At what prices did the RLMD CEO buy Relmada Therapeutics shares?

The 27,500 shares were bought at a weighted average price of $4.12 per share, with individual purchase prices ranging from $4.10 to $4.12 per share.

How many Relmada Therapeutics (RLMD) shares does the CEO own after this transaction?

After the reported purchase, Sergio Traversa beneficially owns 1,300,000 shares of Relmada Therapeutics common stock, held directly.

What stock appreciation rights were granted to the Relmada Therapeutics CEO?

The filing reports a grant of 1,198,000 stock appreciation rights with a conversion or exercise price of $4.06, each tied to one share of common stock.

When do the CEO’s Relmada Therapeutics stock appreciation rights vest and expire?

The stock appreciation rights vest in 16 equal quarterly installments starting on March 12, 2026 and have an expiration date of December 12, 2035.

How many derivative securities does the CEO hold after this Relmada Therapeutics transaction?

Following the transaction, the filing lists 1,198,000 derivative securities (stock appreciation rights) as beneficially owned directly by Sergio Traversa.

Is this Relmada Therapeutics (RLMD) report filed by one or multiple insiders?

The document indicates that it is a Form filed by one reporting person, identifying Sergio Traversa as the sole reporting insider.